Amikacin hydrate (BAY 41-6551 hydrate) is anaminoglycosideantibiotic and a semisynthetic analog of kanamycin. Amikacin hydrate is bactericidal, acting directly on the 30S and 50S bacerial ribosomal subunits to inhibit protein synthesis. Amikacin hydrate is very active against mostGram-negative bacteriaincludinggentamicin- andtobramycin-resistant strains. Amikacin hydrate also inhibits the infections caused by susceptibleNocardiaandnontuberculous mycobacteria^[1][2].

Amikacin offers definite advantages for treating infections caused by organisms resistant to other aminoglycosides. Amikaci is affected by relatively few arninoglycoside-modifying enzymes. Amikacin is useful in the treatment of infections caused byNocardia asteroides,Mycobacterium avium-intracellulare, and certain species of "rapid-growing" mycobacteria (that is,M. chelonaeandM. fortuitumi)^[1].
Amikacin (100-1500 μM) causes a reliable dose-dependent loss of lateral line zebrafish hair cells with a LD₅₀value of 453 μM^[3].

Amikacin (320 mg/kg; subcutaneous injection; daily; for 10 days; male Fischer rats) treatment increases the chance of serious hearing loss in rats in vivo^[3].

408.51

C₂₀H₂₈N₂O₅S

1257517-67-1

阿米卡星水合物；丁胺卡那霉素水合物

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

H₂O : 100 mg/mL(244.79 mM;Need ultrasonic and warming)

DMSO :< 1 mg/mL(insoluble or slightly soluble)